ETHYOL® (amifostine) is an organic thiophosphate cytoprotective agent.
ETHYOL® (amifostine) is indicated to reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer or non-small cell lung cancer.
ETHYOL® is indicated to reduce the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer, where the radiation port includes a substantial portion of the parotid glands (Clinical Studies).
For the approved indications, the clinical data do not suggest that the effectiveness of cisplatin based chemotherapy regimens or radiation therapy is altered by ETHYOL® . There are at present only limited data on the effects of ETHYOL® on the efficacy of chemotherapy or radiotherapy in other settings. ETHYOL® should not be administered to patients in other settings where chemotherapy can produce a significant survival benefit or cure, or in patients receiving definitive radiotherapy, except in the context of a clinical study (see WARNINGS).
Published Studies Related to Ethyol (Amifostine)
Subcutaneous compared with intravenous administration of amifostine in patients with head and neck cancer receiving radiotherapy: final results of the GORTEC2000-02 phase III randomized trial. [2011.01.10]
PURPOSE: To compare compliance with and efficacy of intravenous (IV) and subcutaneous (SC) amifostine for the treatment of patients undergoing radiotherapy for head and neck cancer... CONCLUSION: SC amifostine administration was not significantly superior to IV amifostine administration in terms of patient compliance or efficacy.
Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children's Oncology Group. [2009.12.15]
BACKGROUND: The current study was conducted to determine whether amifostine is effective in reducing the toxicities associated with the administration of platinum-containing regimens in children with hepatoblastoma (HB)... CONCLUSIONS: Amifostine in the doses and schedule used in this study failed to significantly reduce the incidence of platinum-induced toxicities in patients with HB. Copyright (c) 2009 American Cancer Society.
Amifostine has the potential to induce haematologic responses and decelerate disease progression in individual patients with low- and intermediate-1-risk myelodysplastic syndromes. [2009.09]
Myelodysplastic syndromes (MDS) are characterized by hypercellular bone marrow, peripheral cytopenia and an increased rate of intramedullary apoptosis. Oxidative stress is known as an important factor that leads to apoptosis in MDS.
Randomized phase 2 study of subcutaneous amifostine versus epoetin-alpha given 3 times weekly during concurrent chemotherapy and hyperfractionated radiotherapy for limited-disease small cell lung cancer. [2008.10.01]
BACKGROUND: The purpose of the current study was to investigate the role of amifostine and epoetin-alpha in reducing severe toxicities during concurrent chemo-hyperfractionated radiotherapy (CCRT) for limited disease small cell lung cancer (LD-SCLC)... CONCLUSIONS: Although amifostine administered 3 times weekly during CCRT did not significantly reduce severe toxicities, epoetin-alpha was effective in preventing severe anemia during CCRT in patients with LD-SCLC. Other radioprotective strategies to minimize severe toxicities should be investigated.
Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin. [2007.09]
Amifostine has emerged as a pancytoprotectant shown protection against nephrotoxicity, neurotoxicity and ototoxicity in preclinical studies... CONCLUSION: amifostine did not reduce the ototoxicity and nephrotoxicity of our treatment regime. It was not well tolerated due to emesis. It is a selective cytoprotectant without reducing the effect of chemotherapy.
Clinical Trials Related to Ethyol (Amifostine)
Toxicities Associated With Subcutaneous Administration of Ethyol (Amifostine) for the Prevention of Radiation-Induced Toxicities [Completed]
Dry mouth occurs very often in patients who receive radiation treatment. Amifostine is a
drug approved to reduce the short and long-term occurrence of dry mouth when patients receive
radiation treatment for head and neck cancer. Some studies have shown that Amifostine
reduces the side effects of radiation treatment for lung cancer. The use of Amifostine is
still being investigated in lung malignancies. Amifostine is found to be a protectant from
radiation side effects of such normal tissues as bone marrow, skin, oral mucosal, esophagus,
kidney and testes. Patients that receive radiation treatments for lung cancer may experience
side effects involving the esophagus. It is hoped that patients will benefit from the
protection of their esophagus and avoid delays in radiation treatment due to side effects of
Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma [Recruiting]
RATIONALE: Giving chemotherapy drugs, such as melphalan, work in different ways to stop the
growth of cancer cells, either by killing the cells or by stopping them from dividing.
Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of
chemotherapy. Giving chemotherapy with a peripheral stem cell transplant once or twice,
using stem cells from the patient or an identical brother or sister, may allow more
chemotherapy to be given so more cancer cells are killed. Giving maintenance therapy after a
stem cell transplant may kill any cancer cells that remain. It is not yet known which dose
of melphalan is more effective in treating multiple myeloma (MM).
PURPOSE: This randomized phase III trial is studying two different doses of melphalan to
compare how well they work when given together with amifostine followed by one or two
autologous or syngeneic stem cell transplants and maintenance therapy in treating patients
with stage II-III MM
Study Evaluating the Addition of Amifostine (Ethyol®) to Idarubicin and Cytosine Arabinoside in Older Patients With Acute Myeloid Leukemia [Active, not recruiting]
The primary objectives of this study are:
1. To evaluate whether the addition of amifostine will allow for the safe administration of
idarubicin at a dose of 21 mg/m² in combination with standard-dose ara-C in older
patients with newly diagnosed, previously untreated acute myeloid leukemia (AML); and
2. To estimate the complete remission rate of induction therapy with amifostine, idarubicin
(21 mg/m²), plus ara-C or induction therapy with idarubicin (12 mg/m²) plus ara-C in
this patient population.
Amifostine for Head and Neck Irradiation in Lymphoma [Active, not recruiting]
Determination of Amifostine Levels During Radiation Therapy [Completed]
Currently, there are no published methods for easily determining the level of amifostine in
the blood or saliva. A method has been developed within the Department of Radiation Oncology
by Drs. Douglas Spitz and Gurminder Sidhu, within the Spitz Lab. This method has been tested
using both animal sampling and expired blood (obtained from DeGowin blood center) mixed with
If the method proves successful, it could then be used as a tool to quantify blood and
salivary amifostine levels and possibly correlate them to treatment efficacy or limiting
adverse events using amifostine. A better method of treatment, either increasing the efficacy
of amifostine or reducing its unwanted side effects, could then be developed.